查詢結果分析
相關文獻
- Intrapleural Urokinase Treatment in Children with Complicated Parapneumonic Effusion
- Favorable Outcome of Parapneumonic Empyema in Children Managed by Primary Video-Assisted Thoracoscopic Debridement
- Thoracic Empyema in Children: Early Surgical Intervention Hastens Recovery
- Intrapleural Fibrinolytic Treatment of Childhood Empyema
- Child Transitional Object Attachment: Nature, Development, and Related Factors
- 兒童呼吸道感染引發肺旁積液的處理
- 散布性交易訊息刑罰化合憲否
- The Effectiveness of Chest Ultrasonography in Differentiating Empyema from Simple Parapneumonic Effusion
- Pneumococcal Pneumonia with Empyema and Hemolytic Uremic Syndrome in Children: Report of Three Cases
- 胸腔鏡肋膜腔清創術治療兒童因肺炎引發膿胸之經驗
頁籤選單縮合
題 名 | Intrapleural Urokinase Treatment in Children with Complicated Parapneumonic Effusion=肋膜間尿素激酶治療兒童複雜性肺炎併發肋膜積水 |
---|---|
作 者 | 陳榮賓; 呂克桓; 劉淑智; 鄭森隆; 許績男; | 書刊名 | 臺灣兒科醫學會雜誌 |
卷 期 | 47:2 民95.03-04 |
頁 次 | 頁61-66+104 |
分類號 | 417.5351 |
關鍵詞 | 尿素激酶; 肺炎併發複雜性肋膜積水; 膿胸; 兒童; Urokinase; Complicated parapneumonic effusion; Empyema; Children; |
語 文 | 英文(English) |
中文摘要 | 利用肋膜間投與纖維蛋白溶解藥物如尿素激酶已被應用為治療兒童複雜性肺炎併發肋膜積水和膿胸的一種有效的附加治療方法。在這篇研究中,我們描述關於使用尿素激酶用來治療兒童複雜性肺炎併發肋膜積水的經驗。我們回顧13個(平均年齡50.8月)有複雜性肺炎併發肋膜積水或膿胸的病童因對於抗生素和閉管式胸管引流的治療反應不佳,再接受肋膜間投與尿素激酶治療的個案。另外收集13個(平均年齡45.8月)有相同疾病情況的住院病童,皆未使用尿素激酶治療者作為對照組。使用肋膜間尿素激酶療法的病童,在投與尿素激後,最初的24與72小時的肋膜液引流量顯著的多於尿素激酶投與前24小時的引流量(p=0.002與p<0.001)。接受肋膜間投與尿素激酶治療的病童其總肋膜液引流量亦顯著的多於對照組病童(p<0.001)。接受肋膜間尿素激酶治療的病童平均胸管放置引流天數與病童平均總住院天數分別顯著的短於對照組病童(8.7±2.8 days vs. 14.7±6.1 days, p<0.02與15.5±5.3 days vs. 24.4±6.9 days, p=0.002)。13個病人都能成功的以尿素激酶治療改善其肋膜液引流與臨床情況。這13位病童亦沒有發生任何副作用或不適。而對照組中有兩位病童最後需要接受外科清除手術。結論,對於併有複雜性肺炎併發肋膜積水的病童使用肋膜間投與尿素激酶是一種有效且安全的附加治療方法。 |
英文摘要 | Intrapleural instillation of fibrinolytic agent such as urokinase has been shown to be effective as an adjunctive therapy for children with complicated parapneumonic effusion and empyema. In this study, we described our experience with the use of intrapleural urokinase in the management of complicated parapneumonic effusion in children. We collected 13 patients with a mean age of 50.8 months with parapneumonic pleural effusion or empyema; all were treated with intrapleural urokinase after poor response to appropriate antibiotics and simple tube drainage. We also reviewed another 13 patients with a mean age of 45.8 months from the clinical records of children hospitalized with the same conditions prior to urokinase introduction as a control group. The mean fluid drained during the first 24 hours and the first 72 hours after urokinase instillation were significantly greater than those during 24 hours before instillation, p=0.002 and p<0.001, respectively. The total volume of fluid drained was also greater in the urokinase group than that in the control group (p=0.001). The mean duration of chest tube drainage was significantly shorter in the urokinase group (8.7±2.8 days vs. 14.7±6.1 days, p<0.02). The mean length of hospitalization was also significantly shorter in the urokinase group (15.5±5.3 days vs. 24.4±6.9 days, p=0.002). All 13 patients were managed successfully with urokinase treatment without further surgical procedures. None of the patients experienced any side effect or adverse event after urokinase instillation. Two patients of the control group finally underwent surgical debridement. In conclusion, the use of intrapleural urokinase treatment in children with complicated parapneumonic effusion is an effective and safe therapy. |
本系統中英文摘要資訊取自各篇刊載內容。